ArticleFrontiers in pharmacology2021

Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States.

SiNi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.